Highlights AbbVie Inc. Buenos Aires S.E.

Equities

ABBVD

ARBCOM4603M9

End-of-day quote Buenos Aires S.E. Other stock markets 18:00:00 2024-06-26 EDT			5-day change	1st Jan Change
18.05 ^USD	+4.64%		+6.18%	+18.75%

06-28	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT
06-28	AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	06-27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	06-27	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
AbbVie: acquisition of Celsius for $250 million	06-27	CF
AbbVie Buys Celsius Therapeutics for $250 Million	06-27	DJ
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	06-27	MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	06-27	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	06-26	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-26	CI
AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.	06-26	CI
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	06-25	CI
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15	06-21	MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024	06-21	CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	06-20	MT
US FDA proposes to remove switching study requirement for biosimilars	06-20	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AbbVie Inc. Buenos Aires S.E.

Equities

ABBVD

ARBCOM4603M9

Highlights

Filters